Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib with Chemoradiation in Stage III NSCLC
NCT00280150Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2006
- Primary completion
- Jan 2012
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in non-small cell lung cancer (NSCLC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Jan 2006; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00280150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00280150.